Another super posting Mita, thanks! - goes into the broader...

Another super posting Mita, thanks! - goes into the broader benefits of T very nicely and indirectly makes a great case for Axiron et al. It also leads into the broader health argument of trying to resolve the issues pro-actively through diet and exercise, which I am a great believer in, so a win - win !

Chris Kallos of Morningstar has updated his valuation of ACR to $2.00 BTW, rationale as follows :
"We view the advisory panel’s cautionary stance on the category as negative for Axiron and have trimmed our forecasts to reflect the dampening effect of lower product demand. As a result our fair value estimate for no moat-rated Acrux moves to AUD 2.00 from AUD 2.50. This also incorporates a shift of the USD 50 million milestone payment under the Eli Lilly agreement, from fiscal 2015 to fiscal 2016. The shares remain undervalued relative to our fair value estimate but we reiterate that our fair value uncertainty rating is very high. This reflects the largely off-label use of the product and inherent demand volatility of a consumer lifestyle product."